HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: JOE-08-0421v1 200/3/273    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Spiga, F. Articles by Lightman, S. L Search for Related Content PubMed PubMed Citation Articles by Spiga, F. Articles by Lightman, S. L

Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Dorothy Hodgkin Building, Whitson Street, BS1 3NY Bristol, UK¹ Department of Pharmacology, Schering-Plough Corporation, Newhouse, Motherwell, ML15SH UK² Department of Molecular Pharmacology, Schering-Plough Corporation, Newhouse, Motherwell, ML15SH UK

(Correspondence should be addressed to F Spiga; Email: f.spiga{at}bristol.ac.uk)

Vasopressin (AVP), produced in parvocellular neurons of the hypothalamic paraventricular nucleus, regulates, together with CRH, pituitary ACTH secretion. The pituitary actions of AVP are mediated through the G protein receptor V_1b (V_1b|R). In man, hyperactivity of the hypothalamic–pituitary–adrenal axis has been associated with depression and other stress-related conditions. There are also clinical data suggesting a role for AVP in the dysfunctional HPA axis described in some depressed patients. In this study, we have investigated the effect of a recently synthesised selective antagonist of the V_1bR both on exogenous AVP-induced ACTH and corticosterone secretion, and on basal and stress-induced pituitary–adrenal activity. Adult male Sprague-Dawley rats treated with the V_1bR antagonist (Org, 30 mg/kg, s.c.) or vehicle (5% mulgofen in 0.9% saline, 2 ml/kg, s.c.). We found that blockade of the V_1bR reduced the increase in both ACTH and corticosterone secretion induced by AVP (100 ng, i.v.). The same treatment had no effect either on basal ACTH and corticosterone levels or on the ultradian or diurnal rhythms of corticosterone secretion. Acute administration of the V_1bR antagonist reduced ACTH secretion following both restraint and lipopolysaccharide, but did not antagonise the ACTH response to noise. The same treatment did not reduce corticosterone secretion in response to any of the three stressors used in this study. Our results confirm that this compound is an antagonist of the V_1bR in the rat, and that its ability to reduce stress-induced ACTH responses is stressor dependent with differential modulation of pituitary and adrenal responses.

This article has been cited by other articles:

				D. Zelena, A. Domokos, S. K. Jain, R. Jankord, and L. Filaretova The stimuli-specific role of vasopressin in the hypothalamus-pituitary-adrenal axis response to stress J. Endocrinol., August 1, 2009; 202(2): 263 - 278. [Abstract] [Full Text] [PDF]